Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Alzheimer Disease
- Main trialPhase 4
- “The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.”In the company’s words, NCT07633470 on ClinicalTrials.gov
- Other names
- Benzgalantamine
Other drugs for Alzheimer Disease
- Xanomeline/trospium chlorideBristol Myers Squibb · Phase 3
- -APN-1607JYAMS PET Research & Development Limited · Phase 3
- LecanemabEisai · Biogen · Phase 3
- DMB-IBigespas LTD · Phase 3
- TrontinemabRoche · Phase 3
- Buntanetap/posiphenAnnovis Bio Inc. · Phase 3
Coming up1
- Apr 2027Phase 4 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | Apr 2027 | A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026